This bill amends the Controlled Substance, Drug, Device and Cosmetic Act to include tianeptine in Schedule II of controlled substances, recognizing its potential for abuse and associated health risks. Specifically, it adds tianeptine to the list of substances that may lead to severe psychic or physical dependence. The bill also introduces a new section that mandates the Department of Health to monitor adverse health events related to tianeptine, allowing for data collection from various health and law enforcement entities.

Additionally, the Department of Health is tasked with issuing public advisories regarding the dangers of tianeptine exposure when significant health threats arise. The bill outlines the definition of "adverse health event" related to tianeptine, which includes a range of physical, mental, and behavioral conditions resulting from its use or withdrawal. The Department is also empowered to create necessary regulations for reporting and data collection to ensure public safety. This act will take effect 60 days after its passage.

Statutes/Laws affected:
Printer's No. 1067 (Jul 23, 2025): P.L.233, No.64